Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Trifluoperazine
Drug ID BADD_D02281
Description A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Indications and Usage For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Marketing Status approved; investigational
ATC Code N05AB06
DrugBank ID DB00831
KEGG ID D01448; D08636
MeSH ID D014268
PubChem ID 5566
TTD Drug ID D0R4OM
NDC Product Code Not Available
UNII 214IZI85K3
Synonyms Trifluoperazine | Trifluperazine | Trifluoroperazine | Eskazine | Flupazine | Terfluzine | Trifluoperazine Hydrochloride | Trifluoperazine HCL | Triftazin | Apo-Trifluoperazine | Apo Trifluoperazine | ApoTrifluoperazine | Stelazine
Chemical Information
Molecular Formula C21H24F3N3S
CAS Registry Number 117-89-5
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ileus07.13.01.001--
Ileus paralytic07.02.05.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint stiffness15.01.02.003--Not Available
Keratopathy06.06.03.007--Not Available
Laryngeal oedema22.04.02.001; 10.01.05.003; 23.04.01.005--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Megacolon07.02.05.002--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.004--
Muscle spasticity17.05.03.007; 15.05.04.011--
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome12.03.01.003; 17.05.02.003; 15.05.04.015; 08.05.01.005--Not Available
Neuromyopathy17.05.03.003; 15.05.03.010--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.011--
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene